Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective hoisted by Oppenheimer from $200.00 to $216.00 in a research note issued to investors on Thursday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock. Other equities research analysts have also issued reports about the company. Citigroup reduced their price objective on […]
Related Keywords
United States , Neurocrine Biosciences , Eric Benevich , Lindbrook Capital , Neurocrine Biosciences Inc , Benjaminf Edwards Company Inc , Mather Group , Goldman Sachs Group , Needham Company , Wells Fargo Company , Citigroup , Edgerock Capital , Barclays , Free Report , Moderate Buy , Get Free Report , Director Richard , Rock Capital , Neurocrine Biosciences Daily , Nasdaq Nbix , Nbix , Medical , 64125c10 , Boost Price Target , Oppenheimer Holdings Inc ,
vimarsana.com © 2020. All Rights Reserved.